The Alzheimer’s Drug Discovery Foundation (ADDF) awarded three new investments that focus on prevention, including support of the HOPE4MCI Phase 3 trial.
“It is exciting to support a novel idea that has advanced this far,” says Dr. Howard Fillit, founding executive director and chief science officer of the ADDF. “Dr. Gallagher’s research could yield the first drug to slow progression of amnestic mild cognitive impairment, altering the course of Alzheimer’s disease and restoring normal brain function.
“The other two investments build on the wealth of knowledge that we are gaining in area of prevention and will arm clinicians and individuals with better information on reducing risk.”
TREATMENTS
CLINICAL
Michela Gallagher, PhD, Johns Hopkins University and founder of AgeneBio
4th Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Imaging…
